Ascentage Pharma Group reported first-half 2026 revenue of $44.5 million, a 29.3% increase from the prior-year period, driven by product sales of $41.6 million. The company’s cash runway remains sufficient to fund operations and nine registrational programs through the end of 2027, executives said during an earnings call on Thursday.
The biotech firm’s net loss continued, with earnings per share at negative $0.305. Research and development expenses surged 39% year-over-year to $102.8 million, while selling and distribution costs rose 74% to $33.4 million. Administrative expenses increased 26% to $17.5 million. As of June 30, 2026, Ascentage held $279.4 million in cash.
Shares of Ascentage (ticker: AAPG) fell 2.66% to close at $17.55, extending declines from the prior session’s close of $18.03. The stock remains 63.8% below its 52-week high of $48.45 and 3.7% above its 52-week low of $16.36.
Executives highlighted progress across the company’s late-stage hematology and oncology pipeline. Olverembatinib, a third-generation BCR-ABL inhibitor approved in China since 2021 for chronic myeloid leukemia in chronic phase, is being evaluated in global trials POLARIS-1 and POLARIS-2. POLARIS-2, a randomized study against bosutinib, targets completion of enrollment by late 2026 or early 2027, while POLARIS-1, a phase III trial in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, is ongoing.
Lisaftoclax, a selective BCL-2 inhibitor approved in China in July 2025 for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, demonstrated strong efficacy signals. In U.S. frontline myelodysplastic syndrome trials, the therapy achieved an overall response rate of 80%, including a 40% complete response rate. In acute myeloid leukemia trials, lisaftoclax showed an overall complete response or complete response with incomplete hematologic recovery rate of 72%, with a 61% minimal residual disease negativity rate.
Additional pipeline assets include APG-2449, a triple kinase inhibitor covering FAK, ALK, and ROS1; APG-115, an MDM2 inhibitor; and APG-1252, targeting BCL-2 and BCL-xL. The company also noted the progression of GLORIA-2, with enrollment completed at over 400 patients, while GLORIA-3 and GLORIA-4 remain in active stages.
Ascentage’s lisaftoclax is under initial review for inclusion in China’s National Reimbursement Drug List, with expert review meetings scheduled for late August or early September 2026. The company targets potential new drug application filings in the second half of 2027, pending trial outcomes.
